Recruiting soon

Meloxicam vs. Ibuprofen for Pain Control After Wisdom Tooth Removal

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

meloxicam 7,5mg

Drug
Who is being recruted

Facial Pain+7

+ Stomatognathic Diseases

+ Nervous System Diseases

From 18 to 59 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 4
Interventional
Study Start: December 2024
See protocol details

Summary

Principal SponsorUniversidad Austral de Chile
Study ContactCarla C Bertran, DDSMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: December 15, 2024

Actual date on which the first participant was enrolled.

This clinical trial aims to compare the effectiveness of two common pain relief medications, meloxicam and ibuprofen, for managing pain after the removal of wisdom teeth in adults. Wisdom tooth extraction often causes pain and swelling, making it important to find the most effective medication for easing these symptoms and ensuring a smoother recovery. Both meloxicam and ibuprofen are non-steroidal anti-inflammatory drugs (NSAIDs) known for treating mild to moderate postoperative pain. The study seeks to determine which of these drugs offers better pain control following this common dental procedure. Participants in the study will be randomly assigned to receive either meloxicam (7.5 mg) or ibuprofen (400 mg) after their wisdom teeth are removed. The study follows a strict design to ensure reliable results, with neither the participants nor the researchers knowing which medication is being taken by each participant. The effectiveness of each drug will be evaluated based on how well it manages pain after the surgery. This research could help dental professionals make informed decisions about the best pain management strategies for their patients following tooth extractions.

Official TitleAnalgesic Efficacy of Meloxicam Versus Ibuprofen for Pain Control After Third Molar Extraction in Adult Patients: Randomized Clinical Trial
NCT06704113
Principal SponsorUniversidad Austral de Chile
Study ContactCarla C Bertran, DDSMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

68 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 59 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Facial PainStomatognathic DiseasesNervous System DiseasesNeurologic ManifestationsPainSensation DisordersSigns and SymptomsPathological Conditions, Signs and SymptomsTooth DiseasesToothache

Criteria

Inclusion Criteria: Maxillary or mandibular third molar with semi or fully erupted crown. Exclusion Criteria: Patients with Systemic pathologies. Presence of third molar localized infection. Completely included third molar crown. Periodontal compromise. Pregnant or breastfeeding women. Patients with hypersensitivity to NSAIDs. Patients with a history of drug abuse. Patients who had taken any drug in the previous 24 hours. Intervention (exodontia) time longer than 45 minutes.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
Ibuprofen 400mg tablets, 1 every 8 hours for 3 days will be administered for post-surgical pain.

Group II

Active Comparator
Meloxicam 7.5mg tablets, 1 every 12 hours for 3 days will be administered for post-surgical pain.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
Recruiting soonNo study centers
Meloxicam vs. Ibuprofen for Pain Control After Wisdom Tooth Removal | PatLynk